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Bortezomib, the ﬁrst-in-class proteasome inhibitor, has become one of the standard treatments in multiple
myeloma. The agent is thought to exert its antimyeloma effects through the inhibition of NF-kB. However,
evidence suggests that bortezomib also affects additional cell survival pathways, such as the p44/42 mitogen-
activated protein kinase pathway, and inhibitory effects on IL-6, TNF-a, and vascular endothelial growth factor
have also been demonstrated. These diverse effects have prompted the investigation of bortezomib’s activity
in various immune and inﬂammatory processes. This review summarizes the data reported with bortezomib
in the prevention of graft-versus-host disease, antibody-mediated graft rejection, and anti-angiogenesis and
in the treatment of rheumatoid arthritis, multiple sclerosis, and other inﬂammatory diseases. The positive
results obtained suggest a role for bortezomib in these different indications, and therefore further investi-
gations are warranted.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Bortezomib has become one of the most important novel
agents in current multiple myeloma (MM) therapy. This
agent has demonstrated substantial activity in the relapsed/
refractory setting and, more recently, in the frontline setting.
Bortezomib exerts its potent antimyeloma activity in 2
predominant ways: It directly impacts myeloma cell survival
through the down-regulation of growth/survival signaling
pathways and the up-regulation of molecules implicated in
proapoptotic cascades, and it acts on the bone marrow
microenvironment by interfering with the adhesion of MM
cells to bone marrow stromal cells. This inhibits the
production of cytokines in the bone marrow and restricts the
development of tumor-associated blood vessels [1-3].
In addition, accumulating data indicate that the effects of
bortezomib extend beyond the MM cell and that the agent
inﬂuences other processes, such as bone metabolism, renal
function, and immunomodulation. Indeed, the proteasome
plays a crucial role in the degradation of regulatory proteins
such as cell cycle and tumor-suppressor proteins, transcrip-
tion factors, and mutant or damaged proteins. It is therefore
fundamentally involved in the activation and inactivation of
many cellular processes and the maintenance of cellular
homeostasis [4].
Inhibition of the proteasome results in growth arrest and
cell death, which are thought to be due to the induction of an
apoptotic cascade as a result of the rapid accumulation of
regulatory proteins within the cell. The transcription factoredgments on page 1419.
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teasomal activity. In the cytoplasm, bound to its inhibitor I-
kB, NF-kB is inactive. However, in response to stimuli, I-kB is
degraded by the proteasome, thereby releasing NF-kB that,
upon translocation into the nucleus, initiates the transcrip-
tion of a wide range of genes encoding proteins involved in
cell survival, cell adhesion, and cytokine signaling [5].
NF-kB has been found to be constitutively active in some
cancer cells and to be associated with resistance to anti-
cancer therapy [6]. The constitutive activation of NF-kB has
been shown to promote the expression of cytokines with
proinﬂammatory and proangiogenic activities [7]. In MM,
NF-kB activation has been shown to promote growth,
survival, and drug resistance of MM cells in the bone marrow
microenvironment [8,9]. NF-kB has therefore been identiﬁed
as an attractive target for anticancer agents and as a target in
MM in particular. On the other hand, NF-kB is also a key
regulator of proteins involved in immune or inﬂammation
responses [10,11]. The inhibitory action of bortezomib is, in
part, mediated through the stabilization of I-kB, resulting in
the inhibition of NF-kB [1,6]. However, bortezomib also
affects additional cell survival pathways, such as the p44/42
mitogen-activated protein kinase pathway [12]. Further-
more, inhibitory effects on IL-6, TNF-a, and vascular endo-
thelial growth factor have also been demonstrated [2,13,14].
Thus, the multifaceted effects of bortezomib provide the
rationale for the investigation of the agent in different clin-
ical settings.
This review aims to summarize the current research
evidence available on the effects of bortezomib on the
immune system, especially in the context of graft-versus-
host disease (GVHD) and inﬂammatory diseases. Indeed,
aside from the critical role of the proteasome in MHC class I
restricted antigen presentation [15,16], many other aspects ofTransplantation.
Table 1
Effects of Bortezomib on the Immune System
Reference Immunomodulatory Effects Clinical Implications
Allogeneic stem cell transplantation: GVHD
19, 20 Inhibit proliferation and induce apoptosis of CD4(þ) T cells
A. Suppression of the activation and nuclear translocation of nuclear
factor of activated T cells cytoplasmic 2
B. Suppression of expression of the cell surface receptors CD25,
CD28, CD120b, and CD134, as well as the production of IFN-g,
TNF-a, IL-4, and IL-5
Decrease in risk of aGVHD and cGVHD while preserving
graft-versus-malignancy effects
21 Selective depletion of alloreactive T cells
Decreased the production of T helper 1 cytokines in cell cultures
22 Preserve natural regulatory T cells
Allowing the emergence of a distinct suppressor T cell population
(inhibits the proliferation, IFN-g production, and CD40L expression
in stimulated effector T cells)
23, 24* Down-regulation of cytokine production (IL-2 and TNF-a),
inhibition of T cell proliferation, and induction of T cell apoptosis
(graft-versus-tumor effects preserved)
27, 28 NF-kB blockade has an important role in the management of
inﬂammatory eye disease (ocular GVHD)
29 Immune recovery: CD8þ T cell and natural killer cell reconstitution
enhanced with bortezomib
Antibody-mediated graft rejection
33 Effectively causes apoptosis of normal bone marrowederived
plasma cells and may thereby prevent ongoing antibody production
against HLA
Potential therapy to treat donor-speciﬁc HLA antibody in allograft
recipients
34, 35 Prolonged reductions (or elimination of) in DSA levels
Inﬂammatory disorders: RA
56 Inhibitory and proapoptotic activity in splenocytes and ﬁbroblast-
like synoviocytes
Reduction in joint destruction and improvement in symptoms
57 Reduction in the expression of TNF-a, IL-1beta, IL-6, matrix
metalloproteinase 3, cyclo-oxygenase 2, and inducible nitric oxide
synthase
58 Inhibit the release of TNF-a, IL-1b, IL-6, and IL-10 from activated T
cells
Late effects: reduction of T cell activation and an induction of T cell
apoptosis.
Inﬂammatory disorders: multiple sclerosis
59, 60 Reduction in numbers of T cells secreting proinﬂammatory
cytokines (preclinical animal models)
Potential novel therapeutic strategy against inﬂammation-induced
neurodegenerative disease
Inﬂammatory disorders: lupus and psoriasis
61, 62 Suppressed the survival and immunostimulatory function of human
plasmacytoid dendritic cells by inhibiting intracellular trafﬁcking of
nucleic acidesensing Toll-like receptors and by disturbing
endoplasmic reticulum homeostasis (preclinical models)
Potential novel therapeutic strategies
GVHD indicates graft-versus-host disease; aGVHD, acute GVHD; cGVHD, chronic GVHD; DSA, donor-speciﬁc alloantibody; RA, rheumatoid arthritis.
* Bortezomib given during or within 2 days of allogeneic stem cell transplantation.
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as the survival and activation of T and B cells as well as cell
adhesion and migration [10,11]. This has prompted the
investigation of proteasome inhibitors as immunosuppres-
sant therapies. Various studies have found that these agents
affect several aspects of immune and inﬂammatory
responses by interfering with antigen processing, apoptosis,
cell cycle, costimulation, adhesion, and chemotaxis [11].
Bortezomib has been shown to exert potent immunomodu-
latory effects, including the induction of apoptosis of
dendritic cells, decrease in T cell costimulatory molecules
and in inﬂammatory cytokine production, selective apoptosis
of activated effector T cells, increase in effector function, and
inhibition of NF-kB (Table 1) [17,18].
BORTEZOMIB IN GVHD
The observation that NF-kB activation in T cells is neces-
sary for acute allograft rejection [19] provided the rationale
for the investigation of bortezomib in the setting of GVHD. In
vitro, bortezomib was shown to inhibit proliferation andinduce apoptosis of CD4þ T cells by suppressing the activa-
tion and nuclear translocation of nuclear factor of activated T
cells cytoplasmic 2 (NFATc2). As a result, essential immune
functions of human CD4þ T cells were suppressed, as shown
by loss of expression of the cell surface receptors CD25, CD28,
CD120b, and CD134 as well as the decrease of IFN-g, TNF-a,
IL-4, and IL-5 production [20].
Furthermore, bortezomib induced the selective depletion
of alloreactive T lymphocytes anddecreased the production of
T helper 1 cytokines in cell cultures [21]. In addition, treat-
ment of CD4þ T cells with bortezomib was found to preserve
natural regulatory T cells while allowing the emergence of
a distinct suppressor T cell population that inhibited the
proliferation, IFN-g production, and CD40L expression in
stimulated effector T cells [22]. In mice, administration of
bortezomib at the time of allogeneic bone marrow trans-
plantation or within the ﬁrst 2 days after transplantation
resulted in signiﬁcant protection from acute GVHD (aGVHD)
due to the down-regulation of cytokine production (IL-2 and
TNF-a), inhibition of Tcell proliferation, and induction of Tcell
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[23,24]. Interestingly, the timing of bortezomib administra-
tion appears to be crucial, because delayed administration of
the agent until 3 days after transplantation or during GVHD
resulted in signiﬁcant acceleration of GVHD-dependent
morbidity and mortality [25]. Mateos-Mazon et al. [26]
found that bortezomib may be useful in the management of
chronic GVHD (cGVHD). The investigators administered bor-
tezomib to 8 patients who relapsed after reduced-intensity
conditioning allogeneic transplantation [26]. At the time of
bortezomib administration, 4 patients had cGVHD, including
severe punctate keratopathy in 3 patients. Interestingly, in all
4 patients, cGVHD signiﬁcantly improved, especially in the
3 patients with ocular involvement, in whom both symptoms
and conjunctival ulcerations responded. As previously shown
andnoted by the investigators, NF-kB activationplays a crucial
function in inﬂammatory eye disease; therefore, NF-kB
blockade may have an important role in the management of
ocular GVHD [27].
In another study by El-Cheikh et al. [28], bortezomib was
administered as salvage treatment after MM relapse or
progression after allogeneic stem cell transplantation in 37
patients. Before the start of treatment, 8 patients were
suffering limited cGVHD, whereas 3 patients had extensive
signs. During bortezomib treatment, 2 patients experienced
reactivation or worsening of GVHD symptoms, although no
additional immunosuppressive therapy was required. Two of
the 3 patients with extensive cGVHD signs before the start of
treatment showed a signiﬁcant improvement in GVHD and
were staged as limited cGVHD at last follow-up. The
remaining 8 patients with limited cGVHD did not require any
additional immunosuppressive therapy, and in 1 patient
GVHD symptoms were no longer observed.
Finally, Koreth et al. [29] conducted a phase I study to
investigate the combination of bortezomib, tacrolimus, and
methotrexate in 23 patients who had undergone reduced-
intensity conditioning allogeneic stem cell transplantation
using HLA-mismatched unrelated donors. Treatment with
this combination was found to be effective in the prevention
of GVHD, with grades II to IV aGVHD occurring in 3 patients,
whereas cGVHD was observed in 9 patients after a median
follow-up of 12 months. In addition, at 1 year, the nonrelapse
mortality rate was zero, the cumulative incidence of relapse/
progression was 29%, overall survival 75%, progression-free
survival 64%, and event-free survival 59%.
After this phase I trial segment documenting minimal
toxicity and preliminary evidence for aGVHD control, the
same group [30] reported the complete phase I/II results
from this trial. They found that the 180-day cumulative
incidence of grades II to IV aGVHD was 22% (95% conﬁdence
interval, 11% to 35%). One-year cumulative incidence of
cGVHD was 29% (95% conﬁdence interval, 16% to 43%). Most
important, bortezomib-treated HLA-mismatched patients
experienced rates of nonrelapse mortality, aGVHD and
cGVHD, and survival similar to those of contemporaneous
HLA-matched patients who underwent tranplantation at the
same institution. Moreover, immune recovery, including
CD8þ T cell and natural killer cell reconstitution, was
enhanced with bortezomib, suggesting that a novel, short-
course, bortezomib-based GVHD prophylaxis regimen is
attractive and suitable for prospective randomized evalua-
tion. Taken together, the above results demonstrate the
signiﬁcant potential of bortezomib in the prevention of
GVHD due to marked immunomodulatory activity [30]. An
ongoing prospective trial of the Blood and MarrowTransplant Clinical Trials Network is currently investigating
the role of two bortezomib-based prophylaxis of GVHD
(bortezomib-methotrexate and bortezomib-sirolimus) in
reduced-intensity conditioning allogeneic stem cell trans-
plantation (NTC01754389).BORTEZOMIB IN ANTIBODY-MEDIATED GRAFT
REJECTION
Antibody production against HLA presents a major bar-
rier to successful renal transplantation. Antibody-mediated
rejection (AMR) is characterized by a rise in donor-speciﬁc
alloantibody (DSA) in the ﬁrst few weeks after trans-
plantation, and it is believed that pre-existing plasma cells,
as well as the conversion of memory B cells to new plasma
cells, play a role in increased DSA production [31]. Treat-
ments for AMR include the removal of antibodies by plas-
mapheresis or immune adsorption, high-dose pulses of
glucocorticoids, intravenous immunoglobulin, and anti-
proliferative agents [32]. However, these therapies do not
target the mature antibody-producing plasma cell. A prom-
ising approach in the treatment of AMR focuses on borte-
zomib, which has been shown to effectively cause apoptosis
of normal bone marrowederived plasma cells and may
thereby prevent ongoing antibody production against HLA
[33].
In an initial clinical experience reported by Everly et al.
[34], bortezomib treatment in 6 patients with AMR and
concomitant acute cellular rejection resulted in prompt
rejection reversal, marked and prolonged reductions in DSA
levels, improved renal allograft function, and suppression of
recurrent rejection for at least 5 months, suggesting the
agent presents a viable therapy to treat donor-speciﬁc HLA
antibody in allograft recipients. More recent experience
appears to suggest that bortezomib may be particularly
effective for the rapid elimination of DSA in early acute AMR
in renal transplantation recipients [35]. Walsh et al.
described 2 patients with acute AMR that occurred within
the ﬁrst 2 weeks after transplantation, in whom bortezomib
induced prompt AMR reversal and elimination of detectable
DSA within 14 days of initiation of therapy, whereas renal
function was maintained [35]. Interestingly, bortezomib
retreatment for 1 patients who experienced repeated DSA
elevation resulted in complete and durable DSA elimination.
In another report of bortezomib use in the treatment of
AMR after kidney-only or kidney-combined organ trans-
plantation, Flechner et al. [36] noted that bortezomib-
containing regimens appear to be most effective before the
onset of signiﬁcant renal dysfunction or proteinuria, and
concluded that further studies are needed to deﬁne the
optimal strategy for bortezomib use in the treatment of AMR.
A number of groups have now reported on their experiences
with bortezomib for the treatment of AMR, and, collectively,
these studies suggest that bortezomib-induced proteasome
inhibition provides an effective strategy to reduce HLA
antibody levels in transplantation recipients and may
therefore present a promising approach in the treatment of
antibody-AMR [35,37-43]. Also, control of antibody-AMR
could be of relevance to complications after allogeneic
stem cell transplantation (eg, pure red cell aplasia in an ABO
incompatible donorerecipient pair). However, one should
bear in mind that other reports could not conﬁrm the activity
of bortezomib as a desensitization agent, highlighting the
need for prospective, randomized, and well-controlled
studies in the area [44,45].
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Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inﬂammatory auto-
immune disease in which nonspeciﬁc inﬂammation affects
theperipheral joints [46]. It is associatedwith increasing levels
of pain and disability, resulting in considerable morbidity and
premature mortality. Treatment of RA consists of nonsteroi-
dal anti-inﬂammatory agents, corticosteroids, and disease-
modifying antirheumatic drugs, including the more recent
addition of biologic response modiﬁers [47-51].
The proinﬂammatory cytokines TNF-a and IL-1b,
produced primarily by macrophages and ﬁbroblasts, play
a crucial role in the pathogenesis of rheumatoid synovitis
[52-54]. They appear to directly contribute to tissue damage
and to the perpetuation of the inﬂammatory response by
recruiting activated immune and inﬂammatory cells to the
inﬂamed joint. Expression of these cytokines is regulated by
the transcription factor NF-kB, which also regulates many
other genes involved in immune and inﬂammatory
responses, such as IL-6, IL-8, and granulocyte-macrophage
colony-stimulating factor. In addition, activation of NF-kB
has been implicated in the regulation of hyperplasia in the
RA synovium through blocking the apoptosis of synovial
cells. NF-kB has therefore been suggested as a target in RA
[52,55], providing the rationale for the investigation of bor-
tezomib in this disease in different animal models [56,57].
In healthy volunteers and RA patients treated with
methotrexate, bortezomib has been shown to inhibit the
release of TNF-a, IL-1b, IL-6, and IL-10 from activated T cells
[58]. The reduction in cytokines was seen regardless of
a response to methotrexate. In addition, bortezomib treat-
ment was associated with late effects, resulting in a reduc-
tion of T cell activation and an induction of T cell apoptosis.
Based on its mechanism of action, bortezomib presents
a rational choice as a possible anti-inﬂammatory treatment
modality in RA, and the preliminary ﬁndings summarized
above appear to suggest that the agent has activity in this
setting. However, further studies are needed to demonstrate
clinical effects.
Multiple Sclerosis and Other Inﬂammatory Diseases
The anti-inﬂammatory effect of bortezomib resulting
from its inhibitory action on NF-kB has also provided the
rationale for the examination of the agent in other inﬂam-
matory disorders, such as central nervous system and
intestinal inﬂammation, in different animal models [59,60].
In addition, it has been suggested that bortezomib could
present a treatment option in other inﬂammatory disorders,
such as lupus and psoriasis [61,62].
BORTEZOMIB AND ANGIOGENESIS
Bortezomib has been suggested to have anti-angiogenesis
activity, and a study by Roccaro et al. [63] indicates that the
mechanism underlying this activity is the inhibition of
vascular endothelial growth factor and IL-6 secretion by
endothelial cells. The investigators found that treatment of
MM patientederived endothelial cells with bortezomib
resulted in a dose-dependent inhibition of proliferation of
patient-derived endothelial cells as well as angiogenesis. The
antiangiogenic activity is thought to be mediated through
the inhibition of the expression of NF-kBedependent
proangiogenic cytokines [14]. In addition, bortezomib has
been suggested to inhibit the angiogenic and vasculogenic
activity of bone marrowmacrophages by inhibiting their cellproliferation, adhesion, migration, and expression of angio-
genic cytokines (vascular endothelial growth factor, basic
ﬁbroblast growth factor, hepatocyte growth factor, and
platelet-derived growth factor) [64]. Capillarogenic organi-
zation and expression of vascular markers in cells that
became vasculogenic were also found to be inhibited by
bortezomib. Notably, it was found that cotreatment with
zoledronic acid resulted in synergistic inhibitory effects.
CONCLUDING REMARKS
The proteasome plays a vital role in the regulation of
many cellular processes and is therefore an attractive target
for the treatment of a variety of disorders. Bortezomib is
a potent inhibitor of proteasomal activity, which provides the
rationale for the investigation of the agent in cancer and in
immune or inﬂammatory processes. The agent has shown
positive results in the treatment of hematologic malignan-
cies and in the treatment of allograft rejection, GVHD, and
several inﬂammatory disorders. Further studies are war-
ranted to extend the experience with the agent in these
settings and to deﬁne optimal management strategies.
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